Labcorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.
To determine if you are infected with human immunodeficiency virus (HIV)
At least once, when you are 13 to 64 years old; when you think you may have been exposed to the virus; before becoming pregnant or when pregnant; once a year if you are at increased risk of being exposed to the virus
A blood sample collected from a vein in your arm or from a fingerstick; there are also HIV antibody tests available that can be performed on oral fluid.
Human immunodeficiency virus (HIV) is the cause of AIDS (acquired immunodeficiency syndrome). HIV screening tests detect the HIV antigen (p24) and/or HIV antibodies produced in response to an HIV infection in the blood. Some tests detect HIV antibody in oral fluid.
When a person becomes infected with HIV, through exposure to the blood or body fluids of an infected individual or a contaminated needle, for example, the virus begins to replicate itself, producing a large number of copies. During the first few weeks of infection, the amount of virus (viral load) and the p24 antigen level in the blood can be quite high.
About 2-8 weeks after exposure to the virus, the immune system responds by producing antibodies directed against the virus that can be detected in the blood. As the initial infection resolves and the level of HIV antibody increases, both virus and p24 antigen levels decrease in the blood.
An HIV infection may initially cause no symptoms or cause flu-like symptoms that resolve after a week or two. The only way to determine whether a person has been infected is through HIV testing.
If HIV is not detected early and treated, it may become a simmering infection that may cause few symptoms for a decade or more. If the infection is still not treated, eventually symptoms of AIDS emerge and begin to progressively worsen. Over time and without treatment, HIV destroys the immune system and leaves a person's body vulnerable to debilitating infections. (You can read more about this in the article on HIV Infection and AIDS.)
Detecting and diagnosing HIV early in the course of infection is important because:
There are two types of HIV, 1 and 2. HIV-1 is the most common type found in the United States, while HIV-2 has a higher prevalence in parts of Africa.
A few different testing options are available for HIV screening:
Regardless of the type of screening test used, a positive result requires follow up with supplemental testing to establish a diagnosis of HIV.
How is the sample collected for testing?
A blood sample is obtained by inserting a needle into a vein in the arm or from a fingerstick. There also are tests available that can be performed on oral samples. An oral sample is obtained by using a special small, spatula-like device with a flat pad on the end. The flat pad is placed above the teeth against the outer gum and is swabbed completely once around the outer part of the upper and lower gums.
HIV antibody and HIV antigen (p24) testing is used to screen for and diagnose HIV infections. Early detection and treatment of HIV infection and immune system monitoring can greatly improve long-term health and survival. Also, if a person knows his or her HIV status, it may help change behaviors that can put him or her and others at risk.
Different types of tests may be used for HIV screening:
There are a few different ways a person can get access to HIV screening:
If any one of the above screening tests is positive, then it must be followed by a second test to establish a diagnosis. This second test is an antibody test that is different than the first test. If the second test does not agree with the first test, then a third test is performed that detects the genetic material (RNA) of the virus. An HIV RNA test will detect HIV in most people by 1-4 weeks of infection.
Several organizations recommend routine screening for HIV:
For additional details on screening recommendations, see the articles for Teens, Young Adults, Adults, and Adults 50 and Up.
Annual screening is advised for those at high risk for HIV and is recommended when an individual:
Certain individuals should get at least a one-time test, even if they are not between the ages of 13 and 64, and learn their status. These include:
A negative test for HIV antigen and/or HIV antibody usually indicates that a person does not have an HIV infection. A negative screening test means only that there is no evidence of disease at the time of the test, however. It is important for those who are at increased risk of HIV infection to have screening tests performed on a yearly basis to check for possible exposure to the virus.
HIV tests that detect only HIV antibody will not detect an HIV infection soon after exposure, during the window period before the development of antibodies. Most people produce detectable levels of antibody 3 to 12 weeks after exposure. If someone is screened with an HIV antibody test too soon, the result may be negative despite the fact that the person is infected (false negative). If an HIV antibody test is negative but suspicion of exposure remains high, then repeat testing using the HIV antigen/antibody blood test may be required.
If someone tests positive on both the initial screen and supplemental testing, then that person is considered to be infected with HIV.
The CDC recommends use of a new testing protocol to screen for and diagnose HIV infection. The following lists the steps and meaning of test results:
Two tests once commonly used to test for HIV, HIV-1 Western blot and HIV-1 immunofluorescence assay, are not included in this new protocol and should not be used since these tests detect antibody later in the infection (around 28 days) and may give a false-negative result.
HIV infection cannot be cured, but early diagnosis allows for treatment with antiretroviral therapy (ART) that can help to suppress levels of virus in the body (viral load) and greatly improve long-term health. People typically take at least three drugs from two different classes in order to prevent or minimize virus replication and the emergence of drug-resistant strains. Combinations of three or more antiretroviral drugs are referred to as highly active antiretroviral therapy or HAART.
There is currently no vaccine to protect against HIV, but avoiding high-risk activities such as having unprotected sex and sharing needles for injecting drugs can help to prevent its spread. Early diagnosis of HIV infection is important to prevent its transmission to others and to allow evaluation, monitoring, and early treatment of the affected person.
While there is no vaccine, the U.S. Centers for Disease Control and Prevention and the World Health Organization recommend that individuals without HIV infection but at high risk for it consider taking pre-exposure prophylaxis (PrEP), a daily pill to help prevent infection. For people taking PrEP consistently, the risk of HIV infection was up to 92% lower compared to those who didn't take it.
Treatment of HIV-infected mothers during pregnancy, precautions at birth, and avoiding breast-feeding can minimize the risk of passing the infection from mother to child. Giving the antiretroviral drug zidovudine intravenously during labor and delivery and also to the newborn twice a day by mouth for 6 weeks reduces the rate of transmission from 25-33% to about 1-2%. A combination of antiretroviral therapies is most effective at reducing the risk of HIV transmission to the baby.
Healthcare workers can protect themselves from HIV infection by following universal precautions, such as wearing gloves and avoiding needle sticks.
Symptoms of the initial HIV infection can mimic those of influenza and other viral infections. The only reliable way to tell if someone is infected is to get tested. Many people with HIV do not experience symptoms for years after the initial infection or have symptoms that are very similar to symptoms of other illnesses. For more, see this CDC web page: HIV/AIDS Basics.
Currently, there is no cure for HIV infection or AIDS. However, there are therapies that can improve immune function, reduce the risk and/or frequency of opportunistic infections, and prolong life. The U.S. Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents as well as the World Health Organization recommend that all individuals diagnosed with HIV infection receive treatment as soon as possible, including pregnant women. With advances in treatment, individuals with HIV infection are living longer, healthier lives. People typically take at least three drugs from two different classes in order to prevent or minimize virus replication and the emergence of drug-resistant strains. Combinations of three or more antiretroviral drugs are referred to as highly active antiretroviral therapy or HAART. Read the Treatment section of the article on HIV Infection and AIDS for additional details.
Yes. If you test positive for HIV infection, it is important that you tell your healthcare practitioners as well as all current and future sex partners and/or anyone with whom you share needles. Counseling services are often available from the clinic that performed the test or from your healthcare provider that will help you to inform the people who need to know.
Your HIV status, like other medical conditions and test results, is protected by the HIPAA Privacy Rule and cannot be shared with friends, family, or employers without your written permission. Your HIV status may be shared with your healthcare providers who have a "need to know" in order to treat you. Also, in order to determine the incidence of HIV and to provide appropriate prevention and care services, all new cases of HIV are reported to state and local health departments.
Certain testing centers provide either anonymous (your name is never given) or confidential (your name is given but kept private) HIV testing and counseling. The FDA has approved one home testing device that allows you to remain anonymous and to get confidential results. You can also contact your state, county, or city health department to find out where testing may be available.
No. Because maternal antibodies are transferred from mother to baby and stay in the newborn's system for 6-12 months, a different test must be used. A test that detects the genetic material, either an HIV RNA or HIV DNA test, is required.
Sources Used in Current Review
Cennimo, D. (2014 March 26, Updated). HIV Testing Overview. Medscape Drugs & Diseases. [On-line information]. Available online at http://emedicine.medscape.com/article/2061077-overview. Accessed Dec 2015.
Bennett, N. (2014 December 17, Updated). Laboratory Assays in HIV Infection. Medscape Drugs & Diseases. [On-line information]. Available online at http://emedicine.medscape.com/article/1995114-overview#showall. Accessed Dec 2015.
Branson, B. et. al. (2014 June 27). Laboratory testing for the diagnosis of HIV infection : updated recommendations. Centers for Disease Control and Prevention and Association of Public Health Laboratories from CDC Stacks. [On-line information]. Available online at http://stacks.cdc.gov/view/cdc/23447. Accessed Dec 2015.
Centers for Disease Control and Prevention (U.S.). (2014 June). New CDC recommendations for HIV testing in laboratories : a step-by-step account of the approach. CDC Stacks. [On-line information]. Available online at http://stacks.cdc.gov/view/cdc/23563. Accessed Dec 2015.
Bennett, N. and Gilroy, S. (2015 Dec 15, Updated). HIV Disease. Medscape Drugs & Diseases. [On-line information]. Available online at http://emedicine.medscape.com/article/211316-overview. Accessed Dec 2015.
Rivera, D. and Frye, R. (2015June 24, Updated). Pediatric HIV Infection. Medscape Drugs & Diseases. [On-line information]. Available online at http://emedicine.medscape.com/article/965086-overview. Accessed Dec 2015.
(Reviewed March 2015) Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection, Diagnosis of HIV Infection in Infants and Children. AIDSinfo. Available at https://aidsinfo.nih.gov/guidelines/html/2/pediatric-arv-guidelines/55/diagnosis-of-hiv-infection-in-infants-and-children. Accessed January 2016.
(Updated November 2014) World Health Organization. HIV/AIDS Online Q and A. Available online at http://www.who.int/features/qa/71/en/. Accessed January 2016.
(September 2015) World Health Organization. World Health Organization Guideline on When to Start Antiretroviral Therapy and Pre-exposure Prophylaxis in HIV. Available online at http://apps.who.int/iris/bitstream/10665/186275/1/9789241509565_eng.pdf?ua=1. Accessed January 2016.
(January 2016) Centers for Disease Control and Prevention. HIV/AIDs: Basics and Testing. Available online at http://www.cdc.gov/hiv/. Accessed Jan 2016.
Sources Used in Previous Reviews
Thomas, Clayton L., Editor (1997). Taber's Cyclopedic Medical Dictionary. F.A. Davis Company, Philadelphia, PA [18th Edition].
Pagana, Kathleen D. & Pagana, Timothy J. (2001). Mosby's Diagnostic and Laboratory Test Reference 5th Edition: Mosby, Inc., Saint Louis, MO.
Janice K. Pinson MT, MBA. Molecular Business Strategies, Birmingham, MI.
Pagana, Kathleen D. & Pagana, Timothy J. (© 2007). Mosby's Diagnostic and Laboratory Test Reference 8th Edition: Mosby, Inc., Saint Louis, MO. Pp. 23-27.
Clarke, W. and Dufour, D. R., Editors (2006). Contemporary Practice in Clinical Chemistry, AACC Press, Washington, DC. Pp. 487-490.
Bennett, N. and Rose, F. (2008 October 22, Updated). HIV Disease. eMedicine [On-line information]. Available online at http://www.emedicine.com/med/TOPIC24.HTM. Accessed on 10/26/08.
Mayo Clinic Staff (2008 August 9). MayoClinic HIV/AIDS. MayoClinic.com [On-line information]. Available online at http://www.mayoclinic.com/health/hiv-aids/DS00005. Accessed on 10/30/08.
(2005 November, Revised). Human Immunodeficiency Virus (HIV) Introduction. Merck Manual for Healthcare Professionals [On-line information]. Available online at http://www.merck.com/mmpe/sec14/ch192/ch192a.html?qt=HIV&alt=sh. Accessed on 10/30/08.
(2008 September, Reviewed). Human Immunodeficiency Virus – HIV. ARUP Consult [On-line information]. Available online at http://www.arupconsult.com/Topics/InfectiousDz/Viruses/HIV.html. Accessed on 10/30/08.
(2006 September 22). Revised Recommendations for HIV Testing of Adults, Adolescents, and Pregnant Women in Health-Care Settings. CDC MMWR 55(RR14); 1-17 [On-line information]. Available online at http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5514a1.htm. Accessed on 11/1/08.
(January 29, 2009) OraSure Technologies. Oral Fluid—Specimen Collection and Testing Procedures. P. 4. PDF available for download at http://www.orasure.com/uploaded/400.pdf. Accessed February 2009.
(© 1995-2012). Test ID: HIVE HIV-1/-2 Antibody Evaluation, Serum. Mayo Clinic Mayo Medical Laboratories [On-line information]. Available online at http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/9333. Accessed February 2012.
Mayo Clinic staff (2012 January 6). HIV testing. MayoClinic.com [On-line information]. Available online at http://www.mayoclinic.com/health/hiv-testing/MY00954/METHOD=print. Accessed February 2012.
Bennett, N.J. and Gilroy, S. (Updated 2011 November 9) HIV Disease. Medscape Reference [On-line information]. Available online at http://emedicine.medscape.com/article/211316-overview. Accessed February 2012.
Bennett, N. (Updated 2011 July 14). Laboratory Assays in HIV Infection. Medscape Reference [On-line information]. Available online at http://emedicine.medscape.com/article/1995114-overview#showall. Accessed February 2012.
Frequently Asked Questions. CDC National HIV and STD Testing Resources [On-line information]. Available online at http://www.hivtest.org/faq.aspx. Accessed February 2012.
Keller, D. (2011 October 6). HIV Patients Treated Long-Term May Have False-Negative Tests. Medscape Medical News [On-line information]. Available online at http://www.medscape.com/viewarticle/751067. Accessed February 2012.
Delaney, K.P. et. al. Performance of an alternative laboratory-based algorithm for HIV diagnosis in a high-risk population. J Clin Virol (2011), doi:10.1016/j.jcv.2011.09.013.
Masciotra, S. et. al. Evaluation of an alternative HIV diagnostic algorithm using specimens from seroconversion panels and persons with established HIV infections. J Clin Virol (2011), doi:10.1016/j.jcv.2011.09.011.
Wesolowski, L. et. al. Performance of an alternative laboratory-based algorithm for diagnosis of HIV infection utilizing a third generation immunoassay, a rapid HIV-1/HIV-2 differentiation test and a DNA or RNA-based nucleic acid amplification test in persons with established HIV-1 infection and blood donors. J Clin Virol (2011), doi:1016/j.jcv.2011.09.026.
Pagana, K. D. & Pagana, T. J. (© 2011). Mosby's Diagnostic and Laboratory Test Reference 10th Edition: Mosby, Inc., Saint Louis, MO. Pp 544-547.
Clarke, W., Editor (© 2011). Contemporary Practice in Clinical Chemistry 2nd Edition: AACC Press, Washington, DC. Pp 609-612.
(September 26, 2006) Centers for Disease Control and Prevention. Revised Recommendations for HIV Testing of Adults, Adolescents, and Pregnant Women in Health-Care Setting. MMWR 55(RR14);1-17. Available online at http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5514a1.htm. Accessed MayFeb 2012.
Qaseem A, et al. Screening for HIV in Health Care Settings: A Guidance Statement From the American College of Physicians and HIV Medicine Association. Ann Int Med, January 20, 2009 vol. 150 no. 2 125-131. Available online at http://www.annals.org/content/150/2/125.long. Accessed April 2012.